Table IV.

Association of PRNCR1 polymorphisms with clinicopathological characteristics of PCa patients.

	rs13252298				rs1456315			rs7841060			rs7007694
Characteristics	AA	AG	GG	P-value	AA	AG	P-value	TT	TG	P-value	TT	TC	P-value
Age at diagnosis (years), n				0.276			0.275			0.373			0.935
≤65	27	72	27		24	102		23	103		106	20
>65	6	35	11		6	46		6	46		44	8
Stage				0.770			0.107			0.144			0.361
pT1	2	3	3		3	5		3	5		8	0
pT2a	7	17	3		6	21		6	21		23	4
pT2b	1	7	3		0	11		0	11		10	1
pT2c	16	48	19		13	70		14	69		65	18
pT3a	3	9	2		0	14		0	14		12	2
pT3b	4	23	8		8	27		6	29		32	3
PSA at diagnosis (ng/ml), n				0.279			0.571			0.797			0.769
≤4	1	0	1		0	2		0	2		2	0
4–10	17	49	22		13	75		14	74		73	15
>10	15	57	15		17	70		15	72		74	13
Gleason score, n				0.462			0.150			0.483			0.806
≤7	26	79	32		20	117		21	116		116	21
>7	7	26	6		10	30		8	32		33	7
Perineural invasion, n				0.576			0.838			0.680			0.836
Positive	22	67	21		18	92		17	93		92	18
Negative	11	39	17		12	55		12	55		57	10
Surgical margin, n				0.690			0.839			0.679			0.292
Positive	12	44	13		11	58		10	59		61	8
Negative	21	62	25		19	89		19	89		88	20

PRNCR1, prostate cancer-associated non-coding RNA 1; PCa, prostate cancer; PSA, prostate-specific antigen.